Keap1-Nrf2-IN-13 is aKeap1-Nrf2protein–protein interaction (PPI) inhibitor with anIC₅₀value of 0.15 μM. Keap1-Nrf2-IN-13 has strong binding affinities to the Keap1 protein by forminghydrogen bondwith the key polar residues (Asn414, Arg415, Arg483, Gln530). Keap1-Nrf2-IN-13 can be used in the research of oxidative stress-related and inflammatory diseases, including pulmonary fibrosis, chronic obstructive pulmonary disorder (COPD) and cancers^[1].

IC50: 0.15 μM (Keap1-Nrf2 PPI)^[1]

Keap1-Nrf2-IN-13 (compound 21a, 0.5-50 μM) has inhibitory effect against Keap1-Nrf2 protein–protein interaction (PPI) with an IC₅₀value of 0.15 μM (fluorescence polarization (FP) assay)^[1].
Keap1-Nrf2-IN-13 (0.1 mM, 90 min) has metabolic stability in the presence of human liver microsomes^[1].
Keap1-Nrf2-IN-13 forms hydrogen bond interactions with the key polar residues (Asn414, Arg415, Arg483, Gln530), resulting in strong binding affinities to the Keap1 protein (docking assay)^[1].

620.69

C₂₈H₃₂N₂O₁₀S₂

2456294-92-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.